Sterling Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Sterling Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,493	Closed	-$53.5K	–	3314
2026 Q1	$53.5K	Sell	2,493 -1,950	-44%	-$27.5K	﹤0.01%	1610
2025 Q4	$41.4K	Sell	4,443 -283	-6%	-$2.36K	﹤0.01%	1868
2025 Q3	$33.3K	Buy	4,726 +2,871	+155%	+$19.8K	﹤0.01%	1914
2025 Q2	$12.1K	Buy	1,855 +1,708	+1,162%	+$11.7K	﹤0.01%	2011
2025 Q1	$1.17K	Sell	147 -86	-37%	-$926	﹤0.01%	2763
2024 Q4	$2.95K	Buy	233 +168	+258%	+$2.34K	﹤0.01%	2655
2024 Q3	$905	Buy	+65	New	+$927	﹤0.01%	2583

Other funds holding DAWN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sterling Capital Management's DAWN Position: Q2 2026 in Review

Sterling Capital Management sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 2,493 shares — an estimated $53.5K sold.

Sterling Capital Management first reported a position in DAWN in Q3 2024 and held it in 7 quarters. The position peaked at $53.5K in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

Sterling Capital Management reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
Sterling Capital Management sold 2,493 Day One Biopharmaceuticals shares in Q2 2026, an estimated $53.5K.
Sterling Capital Management first reported a position in Day One Biopharmaceuticals in Q3 2024 and held it in 7 quarters.
Sterling Capital Management's Day One Biopharmaceuticals position peaked at $53.5K in Q1 2026.
1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.